Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer

PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. EXPERIMENTAL DESIGN: The HR status of 12 OCCC cell lines was determined using RAD5...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkerson, Paul M, Dedes, Konstantin J, Samartzis, Eleftherios Pierre, Dedes, Ioannis, Lambros, Maryou B, Natrajan, Rachael, Gauthier, Arnaud, Piscuoglio, Salvatore, Töpfer, Chantal, Vukovic, Vesna, Daley, Frances, Weigelt, Britta, Reis-Filho, Jorge S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351612/
https://www.ncbi.nlm.nih.gov/pubmed/28002809
http://dx.doi.org/10.18632/oncotarget.14011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351612/
https://www.ncbi.nlm.nih.gov/pubmed/28002809
http://dx.doi.org/10.18632/oncotarget.14011

Ejemplares similares